| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于修改公司经营范围、变更公司注册资本及修订 《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）于 2025 年 8 月 7 日召开 第四届董事会第八次会议，审议通过了《关于修改公司经营范围、变更公司注册 资本及修订<公司章程>暨授权办理工商变更登记的议案》，同时提请公司股东大 会授权公司管理层或其授权代表办理公司工商登记变更、备案等事宜。现将具体 内容公告如下： 一、变更注册资本 由于公司发行的可转换公司债券于 2022 年 10 月 26 日开始进入转股期，自 2022 年 10 月 26 日至 2025 年 6 月 30 日期间，可转换公司债券转股数为 72,282 股。因此上述事项导致公司总股本由 199,658,096 股增加至 199,730,378 股，公司 注册资本由人民币 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-053 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于召开公司 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司第四届董事会第八次会议审议通过了《关于召开 公司 2025 年第一次临时股东大会的议案》，决定于 2025 年 8 月 25 日 14：00 召 开公司 2025 年第一次临时股东大会，现将有关事项通知如下： 一、 会议基本情况 （一） 股东大会届次：2025 年第一次临时股东大会。 （二）召集人：本次股东大会的召集人为公司董事会。 （三）会议召开的合法性、合规性：第四届董事会第八次会议审议通过了《关 于召开公司 2025 年第一次临时股东大会的议案》。本次股东大会会议召开程序 符合《公司法》《上市公司股东会规则》《深圳证券交易所创业板股票上市规则》 等相关法律法规及《南京药石科技股份有限公司章程》的有关规定。 （四）会议召开日 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-048 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 经审核，监事会认为：《南京药石科技股份有限公司2025年半年度报告》和 《南京药石科技股份有限公司2025年半年度报告摘要》的编制和审核程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 南京药石科技股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）第四届监事会第五次会议 于2025年8月7日以现场结合视频会议方式在公司会议室召开，会议通知已于2025 年7月28日通过电子邮件等方式送达各位监事，通知中包括会议的相关资料，同 时列明了会议的召开时间、地点、内容和方式。本次会议应出席监事人数3人， 实际出席3人，会议由监事会主席张树强先生主持。公司部分高级管理人员列席 会议。本次会议的召集、召开和表决程序 ...

| 证券代码：300725 | 证券简称：药石科技 公告编号：2025-047 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）第四届董事会第八次会议于 2025年8月7日以现场结合视频会议形式在公司会议室召开，以书面方式进行表决。 会议通知已于2025年7月28日通过电子邮件等方式送达各位董事。会议由董事长 杨民民先生召集主持，应出席董事人数7人，实际出席董事人数7人。公司部分高 级管理人员列席会议。本次会议的召集、召开符合《中华人民共和国公司法》（以 下简称"《公司法》"）和《南京药石科技股份有限公司公司章程》等有关规定。 一、 董事会会议审议情况 会议在保证所有董事充分发表意见的前提下，以投票表决方式通过了以下议 案： 1、审议通过了《关于公司<2025 年半年度报告>及其摘要的议案》。 经审核，董事会认为：公司 2025 年半年度报告及其摘要的编制程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 ...

南京药石科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人杨民民、主管会计工作负责人吴娟娟及会计机构负责人(会计 主管人员)王冬月声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当 理解计划、预测与承诺之间的差异。敬请投资者注意投资风险。 公司是全球药物研发领域创新型化学产品和服务供应商。主营业务包括 药物分子砌块的研发、工艺开发、生产和销售；基于药物分子砌块的药物发 现技术平台建设和技术转让；基于药物分子砌块的中间体、原料药开发和生 产服务以及制剂开发和生产服务（CDMO）。公司未来经营中可能面对的风险 有：全球经济环境及贸易政策变动风险、药物研发市场需求下降的风险、市 场竞争加剧风险、行业政策变化的风险、环保和安全生产风险、质量控制风 险 ...

Group 1 - The core viewpoint of the news is that Yaoshi Technology (300725) has shown a significant stock price increase of 18.77% as of July 29, 2025, closing at 53.1 yuan, with a trading volume of 376,400 hands and a transaction amount of 1.881 billion yuan [1] - The company's latest quarterly performance report indicates a total operating revenue of 455 million yuan, representing a year-on-year growth of 20.55%, while the net profit attributable to shareholders decreased by 27.67% to 35.79 million yuan [1] - The company has a current ratio of 3.973, a quick ratio of 2.829, and a debt-to-asset ratio of 38.47%, indicating a strong liquidity position [1] Group 2 - Yaoshi Technology has made investments in 21 companies and participated in 22 bidding projects, showcasing its active engagement in the market [2] - The company holds 35 trademark registrations and 152 patents, reflecting its focus on intellectual property and innovation [2] - Additionally, Yaoshi Technology possesses 44 administrative licenses, indicating compliance with regulatory requirements [2]

Core Insights - The article highlights the rapid development and success of the Nanjing Biopharmaceutical Valley, showcasing the approval of new drugs and the establishment of biotech companies in the region [1][2][4]. Group 1: New Drug Approvals - Nanjing Zhengxiang Pharmaceutical's new flu drug, Jike Shou (Marcelosavir), received approval from the National Medical Products Administration on July 18 [1]. - The antibody drug, Suweishitamon (Enzeshu), developed by Xiansheng Pharmaceutical, was approved just half a month earlier [1]. - The Nanjing Biopharmaceutical Valley has over 200 new drugs in development, with a total of 405 approved drugs, including six new drugs [3]. Group 2: Innovative Drug Development - Jike Shou was developed in just six years, breaking the conventional "three tens" rule of a 10-year development cycle, $1 billion investment, and a success rate below 10% [2]. - The drug demonstrated rapid efficacy, with significant symptom relief achieved in just 23.6 hours during clinical trials [2]. - The success of Zhengxiang Pharmaceutical is attributed to a team of experts returning from the San Francisco Bay Area, focusing on unmet clinical needs in oncology and infectious diseases [2]. Group 3: Company Growth and Listings - Nanjing Weilizhibo Biotechnology successfully listed on the Hong Kong Stock Exchange on July 25, following the earlier listing of Yaojie Ankang [1][5]. - Weilizhibo has developed 14 innovative drug candidates, with six in clinical stages, including the globally leading PD-L1×4-1BB dual antibody [4][5]. - The company’s rapid growth is supported by its pilot production base established in the Biopharmaceutical Valley [5]. Group 4: Ecosystem and Collaboration - The Nanjing Biopharmaceutical Valley fosters a collaborative ecosystem, integrating research, production, and application to support company growth [6][9]. - The establishment of the Nanjing Biopharmaceutical Center has facilitated technology transfer and innovation, with over 1,300 biopharmaceutical companies in the area [6][9]. - The center has partnered with over 100 research institutions and companies, significantly reducing research and development costs [7]. Group 5: Future Development and Urban Integration - The Nanjing Biopharmaceutical Valley aims to become a leading technology city, enhancing living spaces and ecological networks [11]. - Plans include the construction of scenic areas and improved infrastructure to support both innovation and quality of life for residents and professionals [11].

Core Viewpoint - The CXO (Contract Research Organization) sector is experiencing a significant performance improvement, driven by favorable policies and increased demand for innovative drug development in China [1][4]. Group 1: Industry Performance - CXO concept stocks have shown strong activity, with companies like Boteng Co. rising nearly 10% and others like Kanglong Chemical and Yiqiao Shenzhou increasing over 5% [1]. - WuXi AppTec and Boteng Co. have reported mid-year performance forecasts that confirm the trend of improving performance in CXO companies, indicating a potential reversal in industry prosperity [1][2]. - The overall order volume in the CXO industry has shown positive growth, with KaiLaiYing reporting a 20% increase in new orders for 2024 and Kanglong Chemical's laboratory services seeing over 15% growth [3]. Group 2: Company-Specific Insights - WuXi AppTec expects to achieve approximately 20.64% revenue growth year-on-year for the first half of 2025, with adjusted net profit expected to grow by 44.43% [2]. - Boteng Co. anticipates a revenue increase of 15% to 20% for the first half of 2025, marking a significant turnaround to profitability [2][3]. - The improvement in Boteng Co.'s gross margin and overall profitability is attributed to strict cost control and enhanced operational efficiency [3]. Group 3: Market Trends and Valuation - The CXO sector is poised for a "Davis Double Play," where both profitability and valuation are expected to rise simultaneously due to improved demand and a recovering investment environment [4]. - The current valuation of the CXO sector is at a mid-low level compared to historical highs, suggesting potential for upward movement as the market stabilizes [4]. - Analysts predict that the demand for innovative drug development will continue to grow, particularly in the context of new technologies like ADCs (Antibody-Drug Conjugates) [5].

Core Viewpoint - The company, Yaoshi Technology, announced a plan for its shareholder, Nanjing Novicos Venture Capital Partnership, to reduce its holdings in the company, which may impact the stock price and investor sentiment [1]. Group 1: Shareholder Reduction Plan - Nanjing Novicos holds 5,404,744 shares, accounting for 2.7174% of the total share capital after excluding repurchased shares, and plans to reduce its entire stake within three months after the announcement [1]. - The reduction will occur through centralized bidding and block trading, with limits set at 1.00% and 2.00% of the total shares, respectively, over any consecutive 90-day period [1]. - Nanjing Novicos is an employee stock ownership platform established over ten years ago, aimed at binding core employees and promoting business development [1]. Group 2: Background Information - The shares to be reduced were issued before the company's initial public offering, including those transferred after the IPO [2]. - Yang Minmin, the company's controlling shareholder and chairman, is also the executive partner of Nanjing Novicos, making it an acting party of the company [3]. Group 3: Fundraising History - Over the past five years, the company has raised a total of 2.085 billion yuan, including 935 million yuan from a specific issuance in 2020 [5]. - The company issued 11.5 million convertible bonds in 2022, raising a total of 1.15 billion yuan, with net proceeds of approximately 1.143 billion yuan after deducting issuance costs [6].

Group 1 - The core point of the article is that Yaoshi Technology (300725.SZ) announced that its employee stock ownership platform plans to reduce its holdings by up to 2.72% of the company's shares [1] - The employee stock ownership platform, Nanjing Novicos Venture Capital Partnership (Limited Partnership), intends to sell a maximum of 5.4047 million shares within three months after the announcement [1] - The reduction will be executed through centralized bidding and block trading methods, affecting 2.7174% of the total share capital after excluding repurchased shares [1]